Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements (2025 and earlier)

Company Profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:27,100,00042,300,00069,500,00044,300,00078,000,000114,600,000
Cash and cash equivalent12,620,00013,159,00063,458,00016,455,0005,154,00039,196,000
Other undisclosed cash, cash equivalents, and short-term investments14,480,00029,141,0006,042,00027,845,00072,846,00075,404,000
Receivables26,000588,000507,000   
Prepaid expense179,000252,000280,000244,000150,000166,000
Other current assets220,000102,000128,000406,000486,000265,000
Other undisclosed current assets431,000422,000897,000386,000708,000558,000
Total current assets:27,956,00043,664,00071,312,00045,336,00079,344,000115,589,000
Noncurrent Assets
Operating lease, right-of-use asset1,149,0002,217,0003,190,0001,648,0002,327,000
Property, plant and equipment236,000353,000451,000906,0001,462,0002,180,000
Long-term investments and receivables16,123,00021,877,00034,266,00037,225,000  
Long-term investments16,123,00021,877,00034,266,00037,225,000  
Other noncurrent assets89,000129,000236,000414,000513,000463,000
Total noncurrent assets:17,597,00024,576,00038,143,00040,193,0004,302,0002,643,000
TOTAL ASSETS:45,553,00068,240,000109,455,00085,529,00083,646,000118,232,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,518,0003,336,0003,797,0006,069,0004,351,0003,072,000
Employee-related liabilities1,846,0002,225,0001,624,000649,000
Accounts payable1,525,0001,976,0001,565,0003,467,0002,448,0001,998,000
Accrued liabilities993,0001,360,000386,000377,000279,000425,000
Debt     878,000 
Deferred rent credit      160,000
Other undisclosed current liabilities4,351,0007,416,0005,895,0006,080,0004,996,0003,795,000
Total current liabilities:6,869,00010,752,0009,692,00012,149,00010,225,0007,027,000
Noncurrent Liabilities
Long-term debt and lease obligation:   2,601,0001,232,0002,310,000 
Liabilities, other than long-term debt 1,373,000   869,000
Other liabilities      869,000
Operating lease, liability 1,373,0002,601,0001,232,0002,310,000
Other undisclosed noncurrent liabilities   (2,601,000)(1,232,000)  
Total noncurrent liabilities: 1,373,0002,601,0001,232,0002,310,000869,000
Total liabilities:6,869,00012,125,00012,293,00013,381,00012,535,0007,896,000
Equity
Equity, attributable to parent38,684,00056,115,00097,162,00072,148,00071,111,000110,336,000
Common stock5,0005,0005,0003,0003,0003,000
Additional paid in capital374,363,000364,361,000361,669,000295,281,000288,224,000280,840,000
Accumulated other comprehensive income (loss)(967,000)(563,000)1,869,0004,00029,000(34,000)
Accumulated deficit(334,717,000)(307,688,000)(266,381,000)(223,140,000)(217,145,000)(170,473,000)
Total equity:38,684,00056,115,00097,162,00072,148,00071,111,000110,336,000
TOTAL LIABILITIES AND EQUITY:45,553,00068,240,000109,455,00085,529,00083,646,000118,232,000

Income Statement (P&L) (USD)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(23,407,000)(32,565,000)(38,630,000)(43,760,000)(48,854,000)(49,222,000)
Other undisclosed operating income 5,284,00010,005,0004,831,000234,000  
Operating loss:(23,407,000)(32,565,000)(38,630,000)(43,760,000)(48,854,000)(49,222,000)
Nonoperating income
(Investment Income, Nonoperating)
   37,459,000  
Other undisclosed loss from continuing operations before equity method investments, income taxes(3,622,000)     
Loss from continuing operations before equity method investments, income taxes:(27,029,000)(32,565,000)(38,630,000)(6,301,000)(48,854,000)(49,222,000)
Loss from equity method investments      
Other undisclosed income (loss) from continuing operations before income taxes  (8,742,000)(4,611,000)306,0002,182,0002,283,000
Loss from continuing operations:(27,029,000)(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)
Loss before gain (loss) on sale of properties:(43,241,000)(5,995,000)(46,672,000)(46,939,000)
Net loss available to common stockholders, diluted:(27,029,000)(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)

Comprehensive Income (USD)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(27,029,000)(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)
Comprehensive loss:(27,029,000)(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(404,000)(2,432,000)1,865,000(25,000)63,0007,000
Comprehensive loss, net of tax, attributable to parent:(27,433,000)(43,739,000)(41,376,000)(6,020,000)(46,609,000)(46,932,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: